Search results for "Dexamethasone"

showing 10 items of 246 documents

How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia

2014

Abstract Differentiation syndrome (DS), formerly known as retinoic acid syndrome, is a relatively common and potentially severe complication seen in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and/or arsenic trioxide. The full-blown syndrome consists of unexplained fever, weight gain, dyspnea with pulmonary infiltrates, pleuropericardial effusion, hypotension, and renal failure. Most measures currently used for management of DS have very little evidence-based support, and therefore, many remain controversial. Despite the lack of evidence supporting DS prophylaxis, several groups have adopted a preventive strategy with corticosteroids, especially for patie…

AdultMaleAcute promyelocytic leukemiamedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsPremedicationImmunologyTretinoinBiochemistryArsenicalslaw.inventionchemistry.chemical_compoundArsenic TrioxideLeukemia Promyelocytic AcutelawTretinoinInternal medicinemedicineHumansArsenic trioxideIntensive care medicineDexamethasonebusiness.industryOxidesSyndromeCell BiologyHematologymedicine.diseaseIntensive care unitDiscontinuationRetinoic acid syndromeLeukemiachemistryFemalebusinessmedicine.drugBlood
researchProduct

Comparison of Ondansetron versus Clonidine efficacy for prevention of postoperative pain, nausea and vomiting after orthognathic surgeries : a triple…

2018

Background The aim of this randomized controlled triple blind trial was to compare the efficacy of clonidine with dexamethasone versus ondansetron with dexamethasone for postoperative pain, nausea and vomiting prevention in orthognathic surgery patients. Material and Methods In this clinical trial study, 30 consecutive patients with skeletal class III deformities were candidates for orthognathic surgery in Qaem hospital, Mashhad University of medical sciences, Mashhad, Iran from March to November 2017. These subjects were randomly assigned to two equal number groups, ondansetron or clonidine. Patients received either oral ondansetron 8mg or oral clonidine 150μg as premedication, 1 hour befo…

AdultMaleAdolescentNauseamedicine.medical_treatmentOrthognathic surgeryClonidinelaw.inventionOndansetron03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled trialDouble-Blind Method030202 anesthesiologylawmedicineHumansGeneral DentistryDexamethasoneAnalgesicsPain Postoperativebusiness.industryOrthognathic Surgical ProceduresResearch030206 dentistry:CIENCIAS MÉDICAS [UNESCO]OndansetronClonidineTreatment OutcomeOtorhinolaryngologyAnesthesiaPostoperative Nausea and VomitingUNESCO::CIENCIAS MÉDICASVomitingAntiemeticsSurgeryPremedicationFemalemedicine.symptomOral Surgerybusinessmedicine.drug
researchProduct

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multi…

2015

This phase 1/2 study was the first to evaluate the safety and efficacy of the cyclin-dependent kinase (CDK) 4/6-specific inhibitor palbociclib (PD-0332991) in sequential combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. The recommended phase 2 dose was palbociclib 100 mg orally once daily on days 1-12 of a 21-day cycle with bortezomib 1.0 mg/m2 (intravenous) and dexamethasone 20 mg (orally 30 min pre-bortezomib dosing) on days 8 and 11 (early G1 arrest) and days 15 and 18 (cell cycle resumed). Dose-limiting toxicities were primarily cytopenias; most other treatment-related adverse events were grade≤3. At a bortezomib dose lower than that in other combina…

AdultMaleCancer ResearchCombination therapyPyridinesKaplan-Meier EstimatePalbociclibPharmacologyDexamethasoneDrug Administration SchedulePiperazinesBortezomibRecurrenceCyclin-dependent kinaseAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineMultiple myelomaDexamethasoneAgedNeoplasm StagingAged 80 and overbiologybusiness.industryBortezomibCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6HematologyMiddle AgedCell cyclemedicine.diseaseTreatment OutcomeOncologyDrug Resistance NeoplasmPharmacodynamicsRetreatmentbiology.proteinFemaleDrug MonitoringMultiple Myelomabusinessmedicine.drugLeukemia & Lymphoma
researchProduct

Role of ondansetron plus dexamethasone in fractionated chemotherapy.

1993

This randomised, double-blind, parallel-group study was carried out to compare the efficacy and safety profile of ondansetron plus dexamethasone and metoclopramide plus dexamethasone in patients receiving fractionated cisplatin (20-25 mg/m2/day) chemotherapy for the treatment of testicular cancer. An interim analysis of 95 patients showed that the ondansetron regimen was significantly superior compared to the metoclopramide regimen (p0.001). According to the study protocol the study was terminated at this stage. At the time the decision to stop the study was taken, a total of 113 patients had been enrolled and were evaluable on an 'intention to treat' basis. Fifty-six of these had received …

AdultMaleCancer ResearchMetoclopramideAdolescentMetoclopramideVomitingmedicine.medical_treatmentDexamethasoneDrug Administration ScheduleOndansetronTesticular NeoplasmsMedicineHumansIn patientDexamethasoneAgedChemotherapybusiness.industryNauseaGeneral MedicineMiddle AgedOndansetronSafety profileOncologyAnesthesiaCisplatinbusinessmedicine.drugOncology
researchProduct

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With…

2012

Purpose This prospective multicenter phase III study compared the efficacy and safety of a triple combination (bortezomib-thalidomide-dexamethasone [VTD]) versus a dual combination (thalidomide-dexamethasone [TD]) in patients with multiple myeloma (MM) progressing or relapsing after autologous stem-cell transplantation (ASCT). Patients and Methods Overall, 269 patients were randomly assigned to receive bortezomib (1.3 mg/m2 intravenous bolus) or no bortezomib for 1 year, in combination with thalidomide (200 mg per day orally) and dexamethasone (40 mg orally once a day on 4 days once every 3 weeks). Bortezomib was administered on days 1, 4, 8, and 11 with a 10-day rest period (day 12 to day …

AdultMaleCancer Researchmedicine.medical_specialtyTransplantation AutologousGastroenterologyDexamethasoneDisease-Free SurvivalDrug Administration ScheduleSettore MED/01 - Statistica MedicaBortezomib03 medical and health sciences0302 clinical medicineRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAutologous transplantationSurvival rateMultiple myelomaDexamethasoneAgedBortezomibbusiness.industryHazard ratioTranslational research Immune Regulation [ONCOL 3]Middle Agedmedicine.diseaseBoronic AcidsThalidomide3. Good healthSurgeryThalidomideTransplantationTreatment OutcomeOncologyPyrazines030220 oncology & carcinogenesisFemaleMultiple MyelomabusinessStem Cell Transplantation030215 immunologymedicine.drugJournal of Clinical Oncology
researchProduct

Investigation of the prevalence of impacted third molars and the effects of eruption level and angulation on caries development by panoramic radiogra…

2021

This study is aimed to determine the prevalence of impacted third molars and to investigate the effects of their eruption level and angulation on caries formation in the distal of the adjacent tooth. This cross-sectional study was conducted on panoramic radiographs of 38481 patients who were admitted to the Trakya University, Faculty of Dentistry. The panoramic radiographs of 7998 patients with at least one impacted third molar were included. Third molars were classified according to Winter?s classification and Pell and Gregory?s classification. The frequency of caries in partially impacted third molars and adjacent second molars was determined. The chi-square tests were used to determine p…

AdultMaleDental Caries SusceptibilityTooth ImpacteddexamethasoneMandibleMiddle AgedTooth EruptionYoung Adultoral lichen planustopical treatmentCross-Sectional StudiesOtorhinolaryngologyRadiography PanoramicPrevalenceHumansSurgeryFemaleMolar ThirdcyclosporineGeneral DentistryUNESCO:CIENCIAS MÉDICASMedicina oral, patologia oral y cirugia bucal
researchProduct

Weekly monitoring of dexamethasone suppression response in depression: its relationship to change of body weight and psychopathology

1985

Abstract Weekly dexamethasone suppression tests (DST) were performed in 19 hospitalized patients with major depressive disorder, endogenous subtype, and who had an abnormal DST at admission. Depression scores (Hamilton Rating Scale) and weight changes were collected by investigators who were blind to the test results. Major findings were: (1) the DST gradually normalized 3–4 weeks prior to full resolution of clinical symptomatology; (2) weight loss was an important patient variable which may have contributed to false positive DST results; however, the positive correlation between changes in DST results and changes in depression scores in all our patients with or without weight loss suggests…

AdultMaleHypothalamo-Hypophyseal Systemmedicine.medical_specialtyBipolar DisorderHydrocortisonePsychometricsEndocrinology Diabetes and MetabolismPituitary-Adrenal SystemDexamethasoneEndocrinologyRating scaleWeight lossInternal medicinemedicineHumansPsychiatryBiological PsychiatryDexamethasoneDepression (differential diagnoses)AgedDepressive DisorderPsychopathologyEndocrine and Autonomic SystemsBody WeightWeight changeMiddle Agedmedicine.diseasePsychiatry and Mental healthMajor depressive disorderFemalemedicine.symptomPsychologyFollow-Up StudiesPsychopathologymedicine.drugPsychoneuroendocrinology
researchProduct

Adrenal morphology and function in acromegalic patients in relation to disease activity.

2009

Visceromegaly is a common consequence of acromegaly. However, few studies investigated the chronic effects of growth hormone on adrenal glands. Our aim was to evaluate adrenal morphology and function in a cohort of acromegalic patients in relation to disease activity. Twenty-six acromegalics (10 males and 16 females) and 21 healthy subjects were investigated. Gland morphology was evaluated by computerized axial tomography, measuring central, lateral, and medial adrenal segments. Uncontrolled acromegalics showed increased volume of all adrenal segments, higher urinary free cortisol (UFC), and lower morning adrenocorticotropic hormone in comparison with healthy subjects. However, normal corti…

AdultMaleHypothalamo-Hypophyseal Systemmedicine.medical_specialtyEndocrinology Diabetes and MetabolismPituitary-Adrenal SystemAdrenocorticotropic hormoneCardiovascular SystemSeverity of Illness IndexSettore MED/13 - EndocrinologiaEndocrinologyDiabetes mellitusInternal medicineAdrenal GlandsAcromegalymedicineHumansAgedMorningbusiness.industryAdrenal glandCase-control studyOrgan SizeMiddle Agedmedicine.diseaseEndocrinologymedicine.anatomical_structureAcromegaly Growth hormone Adrenal gland CortisolCase-Control StudiesDexamethasone suppression testAcromegalyDisease ProgressionFemalebusinessVisceromegaly
researchProduct

Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

2013

Abstract Background A combination of bortezomib (1.3 mg/m2), melphalan (5 mg/m2), and dexamethasone (40 mg) (BMD), with all three drugs given as a contemporary intravenous administration, was retrospectively evaluated. Patients and methods Fifty previously treated (median 2 previous lines) patients with myeloma (33 relapsed and 17 refractory) were assessed. The first 19 patients were treated with a twice-a-week (days 1, 4, 8, 11, ‘base’ schedule) administration while, in the remaining 31 patients, the three drugs were administered once a week (days 1, 8, 15, 22, ‘weekly’ schedule). Results Side-effects were predictable and manageable, with prominent haematological toxicity, and a better tox…

AdultMaleMelphalanmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsSalvage therapyGastroenterologyDexamethasoneDisease-Free SurvivalDrug Administration ScheduleBortezomibRefractoryRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalMelphalanMultiple myelomaDexamethasoneAgedRetrospective StudiesAged 80 and overBortezomibbusiness.industryHematologyMiddle Agedmedicine.diseaseBoronic AcidsRegimenTreatment OutcomeOncologyPyrazinesInjections IntravenousFemaleMultiple MyelomabusinessFollow-Up Studiesmedicine.drug
researchProduct

Impact of antenatal glucocorticoid therapy and risk of preterm delivery on intelligence in term-born children

2015

Context: Women at risk of preterm delivery are routinely treated with synthetic glucocorticoids (sGCs). Although this therapy substantially reduces neonatal morbidity, concerns remain whether sGC excess may disrupt neurodevelopmental trajectories underlying cognitive functioning. Objective: The present study is the first to disentangle direct effects of antenatal sGC treatment on possible long-term cognitive disadvantages from those of pregnancy complications and prematurity. Design, Setting, and Participants: This cross-sectional study included a mixed-sex cohort of 222 term-born children (aged 6–11 years) consisting of three groups: children of mothers admitted to hospital for threatening…

AdultMaleRisk0301 basic medicinemedicine.medical_specialtyPediatricsTerm BirthCross-sectional studyEndocrinology Diabetes and MetabolismIntelligenceClinical BiochemistryContext (language use)Prenatal careBetamethasoneBiochemistryDexamethasoneCohort Studies03 medical and health sciencesCognitionObstetric Labor Premature0302 clinical medicineEndocrinologyPregnancyHumansMedicineChildGlucocorticoidsIntelligence TestsPregnancybusiness.industryObstetricsBiochemistry (medical)medicine.diseasePregnancy ComplicationsSexual Dysfunction PhysiologicalCross-Sectional Studies030104 developmental biologyPremature birthPrenatal Exposure Delayed EffectsCohortddc:618.97BetamethasoneFemalebusiness030217 neurology & neurosurgerymedicine.drugCohort study
researchProduct